Abstract:Efficient prioritization of bioactive compounds from high throughput screening campaigns is a fundamental challenge for accelerating drug development efforts. In this study, we present the first data-driven approach to simultaneously detect assay interferents and prioritize true bioactive compounds. By analyzing the learning dynamics during training of a gradient boosting model on noisy high throughput screening data using a novel formulation of sample influence, we are able to distinguish between compounds exhibiting the desired biological response and those producing assay artifacts. Therefore, our method enables false positive and true positive detection without relying on prior screens or assay interference mechanisms, making it applicable to any high throughput screening campaign. We demonstrate that our approach consistently excludes assay interferents with different mechanisms and prioritizes biologically relevant compounds more efficiently than all tested baselines, including a retrospective case study simulating its use in a real drug discovery campaign. Finally, our tool is extremely computationally efficient, requiring less than 30 s per assay on low-resource hardware. As such, our findings show that our method is an ideal addition to existing false positive detection tools and can be used to guide further pharmacological optimization after high throughput screening campaigns.

What problem does this paper attempt to address?

### Problems the Paper Aims to Solve This paper aims to address the issue of false positive readings generated during the high-throughput screening (HTS) process in drug discovery. Specifically, the authors propose a new machine learning-assisted method—Minimum Variance Sampling Analysis (MVS-A)—to simultaneously identify false positive compounds and prioritize genuinely bioactive molecules. #### Main Contributions: 1. **Method Innovation**: MVS-A is a novel sample influence formula based on the Gradient Boosting Model (GBM) that can distinguish compounds with expected biological responses from those causing detection interference. 2. **No Prior Information Required**: This method does not rely on prior screening or detection mechanisms, making it applicable to any high-throughput screening activity. 3. **Efficiency**: MVS-A processes large HTS datasets in less than 30 seconds on low-resource hardware. 4. **Performance Evaluation**: Testing on multiple public and industrial datasets demonstrates MVS-A's effectiveness in eliminating false positives and prioritizing truly active compounds. 5. **Case Study**: The practical effectiveness of MVS-A is showcased through simulations of real drug discovery activities. #### Research Background: - High-throughput screening (HTS) plays a crucial role in drug discovery but suffers from the issue of false positive readings. - False positives arise from various causes, including colloidal aggregation and autofluorescence. - Current methods mostly rely on specific interference mechanism assumptions or historical data, limiting their applicability. #### Method Overview: 1. **Train GBM Classifier**: Train on HTS datasets to distinguish active compounds from inactive ones. 2. **Calculate Sample Influence**: Use MVS-A to calculate the influence score of each active compound. 3. **Ranking and Classification**: Rank all HTS results based on MVS-A scores to identify false positives and true positives. #### Experimental Results: - MVS-A outperforms existing rule-based baselines and other data-driven methods in multiple benchmark tests. - Case studies show that MVS-A effectively identifies compounds with higher biological relevance and does not favor chemical groups that are less amenable to further pharmacological optimization. In summary, this paper aims to enhance the efficiency and accuracy of the high-throughput screening process through the MVS-A method, thereby accelerating the drug discovery process.

Machine Learning Assisted Hit Prioritization for High Throughput Screening in Drug Discovery

Machine learning assisted hit prioritization for high throughput screening in drug discovery

Machine Learning-Driven Data Valuation for Optimizing High-Throughput Screening Pipelines

Data Valuation: A novel approach for analyzing high throughput screen data using machine learning

A deep-learning based analysis framework for ultra-high throughput screening time-series data

High-throughput mechanistic screening of non-equilibrium inhibitors by a fully automated data analysis pipeline in early drug-discovery

Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning

Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening

Predicting Combinative Drug Pairs Towards Realistic Screening Via Integrating Heterogeneous Features.

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

Identification of Compounds That Interfere with High‐Throughput Screening Assay Technologies

Hit me with your best shot: Integrated hit discovery for the next generation of drug targets

Unleashing high content screening in hit detection - Benchmarking AI workflows including novelty detection

Synergizing Chemical Structures and Bioassay Descriptions for Enhanced Molecular Property Prediction in Drug Discovery

Deconvoluting Low Yield from Weak Potency in Direct-to-Biology Workflows with Machine Learning

ChemFH: an integrated tool for screening frequent false positives in chemical biology and drug discovery

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Mitigating Molecular Aggregation in Drug Discovery with Predictive Insights from Explainable AI

Improved genome-scale multi-target virtual screening via a novel collaborative filtering approach to cold-start problem

ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery

Combating small molecule aggregation with machine learning